A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors

Cancer Research

Volumn 62, Issue 6, 2002, Pages 1730-1736

  Feuring Buske, Michaela ^a,c,d   Frankel, Arthur E ^b   Alexander, Richard L ^b   Gerhard, Brigitte ^a   Hogge, Donna E ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DENILEUKIN DIFTITOX;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CELL POPULATION; CELL SUSPENSION; CLINICAL ARTICLE; COLONY FORMING CELL; CONTROLLED STUDY; CYTOGENETICS; CYTOTOXICITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; STEM CELL;

ACUTE DISEASE; ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; DIPHTHERIA TOXIN; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERLEUKIN-3; LEUKEMIA, MONOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; MYELOID PROGENITOR CELLS; RECOMBINANT FUSION PROTEINS; TUMOR STEM CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037085927     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Clinical trials of adults with acute myelogenous leukemia: Experience of the Eastern Cooperative Oncology Group
2. Long-term survival in acute myeloid leukemia: The Eastern Cooperative Oncology Group experience
3. Cellular interactions in erythroblastic islands in long-term bone marrow cultures, as studied by time-lapse video
4. -cases
5. MDRI gene expression and treatment outcome in acute myeloid leukemia
6. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia
7. Association of bcl-2, bax, bcl-xL and interleukin-1 β-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia
8. Structure and activity of diphtheria toxin. II. Attack by trypsin at a specific site within the intact toxin molecule
9. Structure and activity of diphtheria toxin. I. Thiol-dependent dissociation of a fraction of toxin into enzymically active and inactive fragments
10. Rapid entry of nicked diphtheria toxin into cell at low pH. Characterization of the entry process and effects of low pH on the toxin molecule
11. The entry of diphtheria toxin into the mammalian cell cytoplasm: Evidence for lysosomal involvement
12. Adenosine diphosphate ribosylation of aminoacyl transferase II and inhibition of protein synthesis by diphtheria toxin
13. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell
14. Targeted toxin therapy for the treatment of cancer
15. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein
16. In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein
17. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein
18. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells
19. Reactivity of murine cytokine fusion toxin, diphtheria toxin390-murine interleukin-3 (DT390-mIL-3), with bone marrow progenitor cells
20. 390-mIL-3 fusion immunotoxin: Ex vivo and in vivo studies in mice
21. Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term co-culture with supportive feeder layers and cytokines
22. Hematopoietic growth factors and their receptors in acute leukemia
23. Interleukin-3, GM-CSF G-CSF receptor expression on cell lines and primary leukemia cells: Receptor heterogeneity and relationship to growth factor responsiveness
24. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias
25. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor
26. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein
27. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group
28. Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features
29. Enhanced detection, maintenance, and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human Steel factor, interleukin-3, and granulocyte colony-stimulating factor
30. Identification of properties that can distinguish primitive populations of stromal cell-responsive lympho-myeloid cells from cells that are stromal cell-responsive but lymphoid-restricted, and cells that have lymphomyeloid potential but are also capable of competitively repopulating myeloablated recipients
31. Characterization of a hierarchy in human acute myeloid leukemia progenitor cells
32. Multiple defects in innate and adaptive immunologic function in NOD/LtSzscid mice
33. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice
34. Functional differences between transplantable human hematopoietic stem cells from fetal liver, cord blood, and adult marrow
35. Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice
36. The interleukin-3 receptor a chain is a unique marker for human acute myelogenous leukemia stem cells
37. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
38. Expression of Hox genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells
39. -
40. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice
41. Lack of expression of Thy-I (CD90) on acute myeloid leukaemia cells with long-term proliferative ability in vitro and in vivo
42. -progenitor cells from patients with acute myeloid leukemia
43. Two distinct functional high affinity receptors for mouse interleukin-3 (IL-3)
44. Expression cloning of the human IL-3 receptor cDNA reveals a shared β subunit for the human IL-3 and GM-CSF receptors
45. -) hematopoietic cells show altered expression of a subset of genes associated with early cytokine and differentiation responses of their adult counterparts
46. 2microglobulin-null mice
47. Functional reconstitution of the human interleukin- 3 receptor
48. Expression and factor-dependent modulation of the interleukin-3 receptor subunits on human hematopoietic cells
49. Requirements for prolonged action in the cytosol for optimal protein synthesis inhibition by diphtheria toxin
50. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells
51. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide
52. Lambert Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors
53. Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma
54. Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action
55. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte- macrophage colony stimulating factor (GM), during a Phase I trial of patients with relapsed or refractory acute myeloid leukemia
56. Interleukin-3 and interleukin-3 receptors in the brain
57. Expression of IL-3 receptor in testis
58. IL-3 receptor expression, regulation, and function in cells of the vasculature